论文部分内容阅读
目的:探讨肝癌缺失基因2(DLC2)和RhoA蛋白在肝癌组织中的表达及其与预后的关系。方法:采用Western印迹法和免疫组化技术检测128例原发性肝癌组织中DLC2蛋白和RhoA蛋白的表达;分析DLC2蛋白的表达与肝癌临床病理特征的关系及DLC2蛋白对原发性肝癌预后的价值。结果:DLC2蛋白在HCC组织中的表达较癌旁组织低,差异具有统计学意义(P<0.05)。DLC2蛋白在细胞分化程度差的肝癌组织中表达降低(P<0.05)。同时,DLC2蛋白的低表达与RhoA蛋白的高表达呈正相关。DLC2蛋白表达低的原发性肝癌患者预后更差。结论:原发性肝癌组织中DLC2蛋白的低表达与较差的细胞分化程度,RhoA蛋白的高表达相关,DLC2缺失表达的原发性肝癌患者预后较差。
Objective: To investigate the relationship between the expression of DLC2 and RhoA in hepatocellular carcinoma and its relationship with prognosis. Methods: Western blotting and immunohistochemistry were used to detect the expression of DLC2 protein and RhoA protein in 128 cases of primary hepatocellular carcinoma. The relationship between the expression of DLC2 protein and the clinicopathological features of hepatocellular carcinoma and the relationship between DLC2 protein and the prognosis of primary hepatocellular carcinoma value. Results: The expression of DLC2 protein in HCC tissues was lower than that in paracancer tissues (P <0.05). The expression of DLC2 protein was lower in HCC tissues with poor cell differentiation (P <0.05). Meanwhile, the low expression of DLC2 protein was positively correlated with the high expression of RhoA protein. Patients with low primary DLC2 protein expression have worse prognosis. Conclusion: The low expression of DLC2 protein in primary hepatocellular carcinoma is associated with poor cell differentiation and high expression of RhoA protein. The prognosis of patients with primary liver cancer with DLC2 deletion is poor.